Weight Management
GLP-1 programs including semaglutide and tirzepatide for medically supervised weight loss.
About this treatment area
GLP-1 receptor agonists have transformed medical weight management. Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are FDA-approved for chronic weight management and produce average weight loss of 15–22% of body weight in clinical trials. Compounded versions are available through licensed 503A/503B pharmacies at lower cost, though FDA has restricted compounding as shortages resolved.
Relevant peptides
Regulatory status as of September 2026. Always confirm with your provider.
Semaglutide
FDA-approved
GLP-1 receptor agonist. FDA-approved as Wegovy (weight) and Ozempic (diabetes). Weekly injection.
Tirzepatide
FDA-approved
Dual GIP/GLP-1 agonist. FDA-approved as Zepbound and Mounjaro. Highest efficacy in trials.
Liraglutide
FDA-approved
Daily GLP-1 agonist. FDA-approved as Saxenda. Generic available since 2025.
Retatrutide
Research only
Triple agonist in Phase 3 trials. Not approved. Any online “reta” is gray market.
AOD-9604
Compoundable
HGH fragment peptide. Limited human data. Available via compounding.
Cagrilintide
Research only
Amylin analogue in development (CagriSema). Not approved.